Navigation Links
In a Down Economy, Women's Health Company Announces Growth
Date:11/13/2008

ern for her personally while providing an exciting opportunity for her company.

"The gap in developing treatments unique to women is widening even though there are significant unmet needs," Tringali DiPiano says. "Without question our expansion into CNS is an indication of our continued growth and commitment to women and their unique health needs."

The women's health sector represents an estimated $116 billion market by the year 2010, according to a report by Research and Markets.com.


'/>"/>
SOURCE FemmePharma Global Healthcare, Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Economy, Health Care, and Gas Prices Top Issues for Women Business Owners
2. Ban on betting would boost ailing economy, gambling critic says
3. Despite U.S. economy, more Americans seeking cosmetic surgery overseas
4. Womenshealthchannel Enhancements Support Pregnant Teens
5. Penn study finds pro-death proteins required to regulate healthy immune function
6. UCLA researchers identify markers that may predict diabetes in still-healthy people
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. More proof needed of safety and quality of electronic personal health records
9. Health care incentive model offers collaborative approach
10. Loneliness is bad for your health
11. Mailman School of Public Health study examines link between racial discrimination and substance use
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 1RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 2RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 3RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 4Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 2Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 3Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 4Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 5Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 6